Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Precise anti-cancer drug development focuses on targeted therapies.
• Trophoblast cell surface antigen 2 (Trop-2) is a promising target due to its high expression in solid tumors and low expression in normal tissues.
• Trop-2-targeted antibody-drug conjugates (ADCs) demonstrate significant efficacy in treating breast cancer and urothelial carcinoma.

Purpose of the Study:

• To review current clinical trials and combination therapy strategies for Trop-2-targeted ADCs.
• To discuss the limitations of Trop-2-targeted ADCs, including efficacy, toxicity, and biomarker identification.
• To offer insights for future advancements in Trop-2-targeted cancer therapy.

Main Methods:

• Literature review of clinical trials involving Trop-2-targeted ADCs.
• Analysis of combination therapy approaches.
• Discussion of challenges and future directions in the field.

Main Results:

• Trop-2 ADCs have shown promising efficacy in specific solid tumors.
• Clinical application is currently limited by suboptimal efficacy, significant toxicity, and a lack of predictive biomarkers.
• Combination therapies are being explored to enhance treatment outcomes.

Conclusions:

• Trop-2 remains an attractive target for antibody-drug conjugate development.
• Addressing current limitations is crucial for expanding the clinical utility of Trop-2 ADCs.
• Future research should focus on improving efficacy, reducing toxicity, and identifying reliable biomarkers for patient selection.